Is IFRX or ESLA more profitable?

Estrella Immunopharma's return on equity of 0.00% beat InflaRx's return on equity. Company Net Margins Return on Equity Return on Assets InflaRx N/A -88.30% -65.77% Estrella Immunopharma N/A N/A -397.36%

Does the media favor ASRT or ESLA?

In the previous week, Assertio and Assertio both had 2 articles in the media. Estrella Immunopharma's average media sentiment score of 0.62 beat Assertio's score of 0.00 indicating that Estrella Immunopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Assertio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Estrella Immunopharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is NRXP or ESLA more profitable?

Company Net Margins Return on Equity Return on Assets NRx Pharmaceuticals N/A N/A -202.92% Estrella Immunopharma N/A N/A -397.36%

Does the media favor NRXP or ESLA?

In the previous week, NRx Pharmaceuticals and NRx Pharmaceuticals both had 2 articles in the media. NRx Pharmaceuticals' average media sentiment score of 1.87 beat Estrella Immunopharma's score of 0.62 indicating that NRx Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NRx Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Estrella Immunopharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, ESLA or NGEN?

NervGen Pharma is trading at a lower price-to-earnings ratio than Estrella Immunopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Estrella Immunopharma N/A N/A -$13.06M -$0.34 N/A NervGen Pharma N/A N/A N/A -$0.09 N/A

Is ESLA or NGEN more profitable?

Company Net Margins Return on Equity Return on Assets Estrella Immunopharma N/A N/A -397.36% NervGen Pharma N/A N/A N/A

Does the media refer more to ESLA or NGEN?

In the previous week, NervGen Pharma had 4 more articles in the media than Estrella Immunopharma. MarketBeat recorded 6 mentions for NervGen Pharma and 2 mentions for Estrella Immunopharma. Estrella Immunopharma's average media sentiment score of 0.62 beat NervGen Pharma's score of 0.56 indicating that Estrella Immunopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Estrella Immunopharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NervGen Pharma 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Is ESLA or UNCY more profitable?

Estrella Immunopharma's return on equity of 0.00% beat Unicycive Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Estrella Immunopharma N/A N/A -397.36% Unicycive Therapeutics N/A -134.69% -84.51%

Does the media refer more to ESLA or UNCY?

In the previous week, Unicycive Therapeutics had 5 more articles in the media than Estrella Immunopharma. MarketBeat recorded 7 mentions for Unicycive Therapeutics and 2 mentions for Estrella Immunopharma. Estrella Immunopharma's average media sentiment score of 0.62 beat Unicycive Therapeutics' score of -0.12 indicating that Estrella Immunopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Estrella Immunopharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Unicycive Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Estrella Immunopharma (ESLA) Competitors

$0.82 -0.06 (-6.81%)

Closing price 07/14/2026 04:00 PM Eastern

Extended Trading

$0.89 +0.07 (+8.58%)

As of 08:25 AM Eastern

Compare

ESLA vs. IFRX, ASRT, NRXP, NGEN, and UNCY

Should you buy Estrella Immunopharma stock or one of its competitors? MarketBeat compares Estrella Immunopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Estrella Immunopharma include InflaRx (IFRX), Assertio (ASRT), NRx Pharmaceuticals (NRXP), NervGen Pharma (NGEN), and Unicycive Therapeutics (UNCY). These companies are all part of the "pharmaceutical products" industry.

How does Estrella Immunopharma compare to InflaRx?

InflaRx (NASDAQ:IFRX) and Estrella Immunopharma (NASDAQ:ESLA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, media sentiment, earnings, institutional ownership, valuation, dividends and profitability.

Estrella Immunopharma has lower revenue, but higher earnings than InflaRx. InflaRx is trading at a lower price-to-earnings ratio than Estrella Immunopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InflaRx	$30K	4,843.43	-$51.63M	-$0.71	N/A
Estrella Immunopharma	N/A	N/A	-$13.06M	-$0.34	N/A

Estrella Immunopharma's return on equity of 0.00% beat InflaRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InflaRx	N/A	-88.30%	-65.77%
Estrella Immunopharma	N/A	N/A	-397.36%

42.4% of InflaRx shares are held by institutional investors. Comparatively, 0.4% of Estrella Immunopharma shares are held by institutional investors. 16.3% of InflaRx shares are held by company insiders. Comparatively, 5.8% of Estrella Immunopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

InflaRx currently has a consensus price target of $7.00, suggesting a potential upside of 248.26%. Estrella Immunopharma has a consensus price target of $8.00, suggesting a potential upside of 880.39%. Given Estrella Immunopharma's higher possible upside, analysts plainly believe Estrella Immunopharma is more favorable than InflaRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InflaRx	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Estrella Immunopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Estrella Immunopharma had 1 more articles in the media than InflaRx. MarketBeat recorded 2 mentions for Estrella Immunopharma and 1 mentions for InflaRx. InflaRx's average media sentiment score of 1.89 beat Estrella Immunopharma's score of 0.62 indicating that InflaRx is being referred to more favorably in the media.

Company	Overall Sentiment
InflaRx	Very Positive
Estrella Immunopharma	Positive

InflaRx has a beta of 2.44, suggesting that its stock price is 144% more volatile than the broader market. Comparatively, Estrella Immunopharma has a beta of 0.85, suggesting that its stock price is 15% less volatile than the broader market.

Summary

InflaRx beats Estrella Immunopharma on 9 of the 15 factors compared between the two stocks.

How does Estrella Immunopharma compare to Assertio?

Assertio (NASDAQ:ASRT) and Estrella Immunopharma (NASDAQ:ESLA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, analyst recommendations, profitability, institutional ownership and valuation.

Assertio has a beta of 0.52, suggesting that its stock price is 48% less volatile than the broader market. Comparatively, Estrella Immunopharma has a beta of 0.85, suggesting that its stock price is 15% less volatile than the broader market.

In the previous week, Assertio and Assertio both had 2 articles in the media. Estrella Immunopharma's average media sentiment score of 0.62 beat Assertio's score of 0.00 indicating that Estrella Immunopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Assertio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Estrella Immunopharma	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Assertio presently has a consensus price target of $22.65, indicating a potential downside of 3.62%. Estrella Immunopharma has a consensus price target of $8.00, indicating a potential upside of 880.39%. Given Estrella Immunopharma's stronger consensus rating and higher possible upside, analysts clearly believe Estrella Immunopharma is more favorable than Assertio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Assertio	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Estrella Immunopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Estrella Immunopharma has a net margin of 0.00% compared to Assertio's net margin of -34.94%. Estrella Immunopharma's return on equity of 0.00% beat Assertio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Assertio	-34.94%	-38.72%	-13.32%
Estrella Immunopharma	N/A	N/A	-397.36%

49.0% of Assertio shares are held by institutional investors. Comparatively, 0.4% of Estrella Immunopharma shares are held by institutional investors. 5.7% of Assertio shares are held by company insiders. Comparatively, 5.8% of Estrella Immunopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Estrella Immunopharma has lower revenue, but higher earnings than Assertio. Assertio is trading at a lower price-to-earnings ratio than Estrella Immunopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Assertio	$118.71M	1.28	-$30.38M	-$5.69	N/A
Estrella Immunopharma	N/A	N/A	-$13.06M	-$0.34	N/A

Summary

Estrella Immunopharma beats Assertio on 11 of the 14 factors compared between the two stocks.

How does Estrella Immunopharma compare to NRx Pharmaceuticals?

NRx Pharmaceuticals (NASDAQ:NRXP) and Estrella Immunopharma (NASDAQ:ESLA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and risk.

4.3% of NRx Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.4% of Estrella Immunopharma shares are owned by institutional investors. 6.4% of NRx Pharmaceuticals shares are owned by company insiders. Comparatively, 5.8% of Estrella Immunopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, NRx Pharmaceuticals and NRx Pharmaceuticals both had 2 articles in the media. NRx Pharmaceuticals' average media sentiment score of 1.87 beat Estrella Immunopharma's score of 0.62 indicating that NRx Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NRx Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Estrella Immunopharma	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Estrella Immunopharma has lower revenue, but higher earnings than NRx Pharmaceuticals. NRx Pharmaceuticals is trading at a lower price-to-earnings ratio than Estrella Immunopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NRx Pharmaceuticals	$1.23M	127.54	-$28.62M	-$1.09	N/A
Estrella Immunopharma	N/A	N/A	-$13.06M	-$0.34	N/A

Company	Net Margins	Return on Equity	Return on Assets
NRx Pharmaceuticals	N/A	N/A	-202.92%
Estrella Immunopharma	N/A	N/A	-397.36%

NRx Pharmaceuticals has a beta of 2.19, suggesting that its stock price is 119% more volatile than the broader market. Comparatively, Estrella Immunopharma has a beta of 0.85, suggesting that its stock price is 15% less volatile than the broader market.

NRx Pharmaceuticals currently has a consensus price target of $38.25, suggesting a potential upside of 783.37%. Estrella Immunopharma has a consensus price target of $8.00, suggesting a potential upside of 880.39%. Given Estrella Immunopharma's higher possible upside, analysts clearly believe Estrella Immunopharma is more favorable than NRx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NRx Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Estrella Immunopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

NRx Pharmaceuticals beats Estrella Immunopharma on 8 of the 12 factors compared between the two stocks.

How does Estrella Immunopharma compare to NervGen Pharma?

Estrella Immunopharma (NASDAQ:ESLA) and NervGen Pharma (NASDAQ:NGEN) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.

Company	Net Margins	Return on Equity	Return on Assets
Estrella Immunopharma	N/A	N/A	-397.36%
NervGen Pharma	N/A	N/A	N/A

NervGen Pharma is trading at a lower price-to-earnings ratio than Estrella Immunopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Estrella Immunopharma	N/A	N/A	-$13.06M	-$0.34	N/A
NervGen Pharma	N/A	N/A	N/A	-$0.09	N/A

0.4% of Estrella Immunopharma shares are held by institutional investors. 5.8% of Estrella Immunopharma shares are held by company insiders. Comparatively, 5.8% of NervGen Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, NervGen Pharma had 4 more articles in the media than Estrella Immunopharma. MarketBeat recorded 6 mentions for NervGen Pharma and 2 mentions for Estrella Immunopharma. Estrella Immunopharma's average media sentiment score of 0.62 beat NervGen Pharma's score of 0.56 indicating that Estrella Immunopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Estrella Immunopharma	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NervGen Pharma	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Estrella Immunopharma presently has a consensus price target of $8.00, suggesting a potential upside of 880.39%. NervGen Pharma has a consensus price target of $14.00, suggesting a potential upside of 704.60%. Given Estrella Immunopharma's higher probable upside, research analysts plainly believe Estrella Immunopharma is more favorable than NervGen Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Estrella Immunopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
NervGen Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83

Summary

NervGen Pharma beats Estrella Immunopharma on 7 of the 11 factors compared between the two stocks.

How does Estrella Immunopharma compare to Unicycive Therapeutics?

Estrella Immunopharma (NASDAQ:ESLA) and Unicycive Therapeutics (NASDAQ:UNCY) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, media sentiment, analyst recommendations, institutional ownership and dividends.

Estrella Immunopharma has a beta of 0.85, meaning that its share price is 15% less volatile than the broader market. Comparatively, Unicycive Therapeutics has a beta of 1.79, meaning that its share price is 79% more volatile than the broader market.

Estrella Immunopharma has higher earnings, but lower revenue than Unicycive Therapeutics. Estrella Immunopharma is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Estrella Immunopharma	N/A	N/A	-$13.06M	-$0.34	N/A
Unicycive Therapeutics	$680K	210.26	-$26.56M	-$2.21	N/A

Estrella Immunopharma's return on equity of 0.00% beat Unicycive Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Estrella Immunopharma	N/A	N/A	-397.36%
Unicycive Therapeutics	N/A	-134.69%	-84.51%

0.4% of Estrella Immunopharma shares are owned by institutional investors. Comparatively, 40.4% of Unicycive Therapeutics shares are owned by institutional investors. 5.8% of Estrella Immunopharma shares are owned by insiders. Comparatively, 6.0% of Unicycive Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Unicycive Therapeutics had 5 more articles in the media than Estrella Immunopharma. MarketBeat recorded 7 mentions for Unicycive Therapeutics and 2 mentions for Estrella Immunopharma. Estrella Immunopharma's average media sentiment score of 0.62 beat Unicycive Therapeutics' score of -0.12 indicating that Estrella Immunopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Estrella Immunopharma	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Unicycive Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Estrella Immunopharma currently has a consensus target price of $8.00, indicating a potential upside of 880.39%. Unicycive Therapeutics has a consensus target price of $21.75, indicating a potential upside of 316.67%. Given Estrella Immunopharma's higher possible upside, research analysts plainly believe Estrella Immunopharma is more favorable than Unicycive Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Estrella Immunopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Unicycive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Unicycive Therapeutics beats Estrella Immunopharma on 9 of the 14 factors compared between the two stocks.

Get Estrella Immunopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ESLA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ESLA vs. The Competition

Export

Metric	Estrella Immunopharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$37.68M	$3.68B	$6.86B	$12.44B
Dividend Yield	N/A	2.19%	2.68%	8.42%
P/E Ratio	-2.40	20.98	26.94	24.38
Price / Sales	N/A	311.10	521.23	91.92
Price / Cash	N/A	143.66	48.59	59.36
Price / Book	-3.02	8.54	10.89	6.33
Net Income	-$13.06M	$23.83M	$3.59B	$331.02M
7 Day Performance	-9.32%	-2.77%	-1.53%	-0.33%
1 Month Performance	-20.78%	5.85%	2.72%	-1.29%
1 Year Performance	-2.39%	52.15%	28.47%	21.30%

Estrella Immunopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ESLA Estrella Immunopharma	2.6485 of 5 stars	$0.82 -6.8%	$8.00 +880.4%	-7.8%	$37.68M	N/A	N/A	N/A	News Coverage
IFRX InflaRx	3.0129 of 5 stars	$2.16 +1.9%	$7.00 +224.1%	+125.3%	$153.26M	$30K	N/A	60
ASRT Assertio	1.5486 of 5 stars	$23.50 flat	$22.65 -3.6%	N/A	$151.81M	$118.71M	N/A	20	News Coverage
NRXP NRx Pharmaceuticals	3.5178 of 5 stars	$3.92 -5.8%	$38.25 +875.8%	+34.9%	$150.71M	$1.23M	N/A	2
NGEN NervGen Pharma	2.3561 of 5 stars	$1.85 -8.0%	$18.00 +873.0%	N/A	$149.17M	N/A	N/A	N/A	News Coverage Analyst Downgrade High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ESLA) was last updated on 7/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Estrella Immunopharma (ESLA) Competitors

ESLA vs. IFRX, ASRT, NRXP, NGEN, and UNCY

How does Estrella Immunopharma compare to InflaRx?

Summary

How does Estrella Immunopharma compare to Assertio?

Summary

How does Estrella Immunopharma compare to NRx Pharmaceuticals?

Summary

How does Estrella Immunopharma compare to NervGen Pharma?

Summary

How does Estrella Immunopharma compare to Unicycive Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ESLA vs. The Competition

Estrella Immunopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Estrella Immunopharma (ESLA) Competitors

ESLA vs. IFRX, ASRT, NRXP, NGEN, and UNCY

How does Estrella Immunopharma compare to InflaRx?

Which has higher valuation and earnings, IFRX or ESLA?

Is IFRX or ESLA more profitable?

Do insiders & institutionals hold more shares of IFRX or ESLA?

Do analysts rate IFRX or ESLA?

Does the media refer more to IFRX or ESLA?

Which has more volatility and risk, IFRX or ESLA?

Summary

How does Estrella Immunopharma compare to Assertio?

Which has more volatility and risk, ASRT or ESLA?

Does the media favor ASRT or ESLA?

Do analysts prefer ASRT or ESLA?

Is ASRT or ESLA more profitable?

Do institutionals & insiders have more ownership in ASRT or ESLA?

Which has stronger earnings & valuation, ASRT or ESLA?

Summary

How does Estrella Immunopharma compare to NRx Pharmaceuticals?

Do institutionals and insiders hold more shares of NRXP or ESLA?

Does the media favor NRXP or ESLA?

Which has higher earnings & valuation, NRXP or ESLA?

Is NRXP or ESLA more profitable?

Which has more volatility & risk, NRXP or ESLA?

Do analysts rate NRXP or ESLA?

Summary

How does Estrella Immunopharma compare to NervGen Pharma?

Is ESLA or NGEN more profitable?

Which has higher valuation & earnings, ESLA or NGEN?

Do institutionals and insiders hold more shares of ESLA or NGEN?

Does the media refer more to ESLA or NGEN?

Do analysts rate ESLA or NGEN?

Summary

How does Estrella Immunopharma compare to Unicycive Therapeutics?

Which has more volatility and risk, ESLA or UNCY?

Which has preferable valuation and earnings, ESLA or UNCY?

Is ESLA or UNCY more profitable?

Do insiders & institutionals have more ownership in ESLA or UNCY?

Does the media refer more to ESLA or UNCY?

Do analysts rate ESLA or UNCY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ESLA vs. The Competition

Estrella Immunopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools